Global Information
회사소개 | 문의 | 비교리스트

간질 : 시장 인사이트, 역학, 시장 예측(2030년)

Epilepsy - Market Insight, Epidemiology and Market Forecast -2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 11월 상품 코드 968232
페이지 정보 영문 455 Pages
가격
US $ 6,950 ₩ 7,768,000 PDF (Single User License)
US $ 13,900 ₩ 15,536,000 PDF (Site License)
US $ 20,850 ₩ 23,304,000 PDF (Global License)


간질 : 시장 인사이트, 역학, 시장 예측(2030년) Epilepsy - Market Insight, Epidemiology and Market Forecast -2030
발행일 : 2020년 11월 페이지 정보 : 영문 455 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

주요 7개국 시장의 간질 총유병자수는 2017년에 7,190,297명으로 판명되었습니다.

간질(Epilepsy)에 대해 조사 분석했으며, 과거·향후 역학, 미국·유럽 5개국(독일, 스페인, 이탈리아, 프랑스, 영국)·일본의 시장 동향에 초점을 맞추어 현재 치료법, 신약, 시장 규모 등에 대한 체계적인 정보를 제공합니다.

목차

제1장 주요 인사이트

제2장 간질 시장 개요

  • 2017년 간질 시장 점유율 분포
  • 2030년 간질 시장 점유율 분포

제3장 주요 요약

제4장 질환 배경과 개요

  • 서론
  • 발작 종류
  • 임상 증상
  • 원인
  • 분류
  • 간질 종류
  • 위험인자
  • 병태생리
  • 진단
  • 간질의 결절성경화증(TSC) 변이

제5장 역학과 환자 집단

  • 주요 조사 결과
  • 주요 7개국의 간질 총유병자수
  • 주요 7개국의 간질로 진단된 총유병자수

제6장 간질의 국가별 역학

  • 미국
  • 유럽 5개국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
  • 일본

제7장 치료

  • 항간질제(AED)
  • 식사요법
  • 수술
  • 간질과의 생활·대처법

제8장 간질에 관한 미국의 가이드라인

제9장 간질에 관한 유럽의 가이드라인

  • 약물 치료
  • TSC 환자의 간질 관리 치료 옵션
  • TSC의 간질 치료 : 임상 권고

제10장 인정된 시설

제11장 미충족 수요

제12장 출시약

  • 주요 경쟁사
  • Valtoco : Neurelis
  • Diacomit : Biocodex
  • Sympazan(clobazam) : Aquestive Therapeutics
  • Lamictal : GlaxoSmithKline
  • Felbatol : Meda Pharmaceuticals
  • Klonopin : Roche
  • Onfi : Lundbeck
  • Epidiolex : Greenwich Biosciences
  • Banzel : Eisai Pharmaceuticals
  • Topamax : Janssen Pharmaceuticals
  • Zonegran : Eisai
  • Fintepla(ZX 008) : Zogenix
  • Nayzilam(midazolam), nasal spray CIV : UCB
  • Xcopri(cenobamate) : SK Life Science
  • H.P. Acthar Gel : Questcor Pharmaceuticals/Mallinckrodt Pharmaceuticals
  • Trokendi XR : Supernus Pharmaceuticals
  • Oxtellar XR : Supernus Pharmaceuticals
  • Zebinix/ Aptiom : Dainippon Sumitomo Pharma/Eisai
  • Sabril : Lundbeck
  • Fycompa : Eisai
  • Vimpat : UCB Biopharma
  • Lyrica : Pfizer
  • Briviact : UCB Biopharma
  • Keppra : UCB Biopharma
  • Neurontin : Pfizer
  • Trileptal : Novartis

제13장 신약

  • 주요 경쟁사
  • Ganaxolone : Marinus Pharmaceuticals
  • AQST-203 : Aquestive Therapeutics
  • Cannabidiol : Insys Therapeutics
  • Padsevonil : UCB
  • Soticlestat(TAK935/OV935) : Takeda/Ovid Therapeutics
  • Zygel(ZYN002) : Zynerba Pharma
  • ACT-709478/NBI-827104 : Idorsia Pharmaceuticals/Neurocrine Biosciences
  • Translarna(ataluren) : PTC Therapeutics
  • Vatiquinone(EPI-743) : PTC Therapeutics
  • JBPOS0101 : BioPharm Solutions
  • Natalizumab : Biogen
  • Staccato Alprazolam : Engage Therapeutics
  • ICV Delivery System of Valproic Acid(CT-010) : Cerebral Therapeutics
  • EPX-100(Clemizole HCl) : Epygenix
  • JZP-385 : Jazz Pharmaceuticals
  • XEN1101 : Xenon Pharmaceuticals
  • PF-06372865/CVL-865 : Pfizer/Cerevel Therapeutics
  • STK-001 : Stoke Therapeutics

제14장 간질 : 주요 7개국 시장 분석

  • 주요 조사 결과
  • 주요 7개국의 간질 시장 규모

제15장 주요 7개국 시장 전망

  • 미국의 시장 규모
  • 유럽 5개국의 시장 규모
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
  • 일본의 시장 규모
  • 시장 진출과 상환

제16장 사례 연구

제17장 시장 성장 촉진요인

제18장 시장 장벽

제19장 SWOT 분석

제20장 부록

제21장 DelveInsight 서비스 내용

제22장 면책사항

제23장 DelveInsight 소개

KSM 20.11.18

List of Tables

  • Table 1 Summary of Epilepsy, Market, Epidemiology and Key Events (2017-2030)
  • Table 2 Total Prevalent Population of Epilepsy in the 7MM (2017-2030)
  • Table 3 Total Diagnosed Prevalent Population of Epilepsy in the 7MM (2017-2030)
  • Table 4 Total Prevalent Population of Epilepsy in the US (2017-2030)
  • Table 5 Total Diagnosed Prevalent Population of Epilepsy in the US (2017-2030)
  • Table 6 Gender-specific Diagnosed Prevalence of Epilepsy in the US (2017-2030)
  • Table 7 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in the US (2017-2030)
  • Table 8 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in the US (2017-2030)
  • Table 9 Total Prevalent Population of Epilepsy in Germany (2017-2030)
  • Table 10 Total Diagnosed Prevalent Population of Epilepsy in Germany (2017-2030)
  • Table 11 Gender-specific Diagnosed Prevalence of Epilepsy in Germany (2017-2030)
  • Table 12 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Germany (2017-2030)
  • Table 13 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Germany (2017-2030)
  • Table 14 Total Prevalent Population of Epilepsy in France (2017-2030)
  • Table 15 Total Prevalent Diagnosed Population of Epilepsy in France (2017-2030)
  • Table 16 Gender-specific Diagnosed Prevalence of Epilepsy in France (2017-2030)
  • Table 17 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in France (2017-2030)
  • Table 18 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in France (2017-2030)
  • Table 19 Total Prevalent Population of Epilepsy in Italy (2017-2030)
  • Table 20 Total Diagnosed Prevalent Population of Epilepsy in Italy (2017-2030)
  • Table 21 Gender-specific Diagnosed Prevalence of Epilepsy in Italy (2017-2030)
  • Table 22 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Italy (2017-2030)
  • Table 23 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Italy (2017-2030)
  • Table 24 Total Prevalent Population of Epilepsy in Spain (2017-2030)
  • Table 25 Total Diagnosed Prevalent Population of Epilepsy in Spain (2017-2030)
  • Table 26 Gender-specific Diagnosed Prevalence of Epilepsy in Spain (2017-2030)
  • Table 27 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Spain (2017-2030)
  • Table 28 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Spain (2017-2030)
  • Table 29 Total Prevalent Population of Epilepsy in the UK (2017-2030)
  • Table 30 Total Diagnosed Prevalent Population of Epilepsy in the UK (2017-2030)
  • Table 31 Gender-specific Diagnosed Prevalence of Epilepsy in the UK (2017-2030)
  • Table 32 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in the UK (2017-2030)
  • Table 33 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in the UK (2017-2030)
  • Table 34 Total Prevalent Population of Epilepsy in Japan (2017-2030)
  • Table 35 Total Diagnosed Prevalent Population of Epilepsy in Japan (2017-2030)
  • Table 36 Gender-specific Diagnosed Prevalence of Epilepsy in Japan (2017-2030)
  • Table 37 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adult in Japan (2017-2030)
  • Table 38 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Japan (2017-2030)
  • Table 39 Comparison of emerging drugs under development
  • Table 40 ZX008, Clinical Trial Description, 2020
  • Table 41 Comparison of emerging drugs under development
  • Table 42 Ganaxolone, Clinical Trial Description,2020
  • Table 43 AQST-203, Clinical Trial Description, 2020
  • Table 44 Cannabidiol, Clinical Trial Description, 2020
  • Table 45 Padsevonil (UCB0942), Clinical Trial Description, 2020
  • Table 46 Soticlestat, Clinical Trial Description, 2020
  • Table 47 ACT-709478, Clinical Trial Description, 2020
  • Table 48 Translarna (ataluren), Clinical Trial Description, 2020
  • Table 49 Vatiquinone, Clinical Trial Description, 2020
  • Table 50 JBPOS0101, Clinical Trial Description; 2020
  • Table 51 Natalizumab, Clinical Trial Description; 2020
  • Table 52 Staccato Alprazolam, Clinical Trial Description; 2020
  • Table 53 CT-010, Clinical Trial Description; 2020
  • Table 54 EPX-100, Clinical Trial Description; 2020
  • Table 55 CX-8998, Clinical Trial Description; 2020
  • Table 56 XEN1101, Clinical Trial Description; 2020
  • Table 57 CVL-865, Clinical Trial Description; 2020
  • Table 58 STK-001, Clinical Trial Description
  • Table 59 Seven Major Market Size of Epilepsy in USD Million (2017-2030)
  • Table 60 Total Market Size of Epilepsy in the US, in USD Million (2017-2030)
  • Table 61 Market size of Epilepsy by current therapies in the US, in USD Million (2017-2030)
  • Table 62 Market size of Epilepsy by emerging therapies in the US, in USD Million (2017-2030)
  • Table 63 Total Market Size of Epilepsy in Germany, in USD Million (2017-2030)
  • Table 64 Market size of Epilepsy by current therapies in Germany, in USD Million (2017-2030)
  • Table 65 Market size of Epilepsy by emerging therapies in Germany, in USD Million (2017-2030)
  • Table 66 Total Market Size of Epilepsy in France, in USD Million (2017-2030)
  • Table 67 Market size of Epilepsy by current therapies in France, in USD Million (2017-2030)
  • Table 68 Market size of Epilepsy by emerging therapies in France, in USD Million (2017-2030)
  • Table 69 Total Market Size of Epilepsy in Italy, in USD Million (2017-2030)
  • Table 70 Market size of Epilepsy by current therapies in Italy, in USD Million (2017-2030)
  • Table 71 Market size of Epilepsy by emerging therapies in Italy, in USD Million (2017-2030)
  • Table 72 Total Market Size of Epilepsy in Spain, in USD Million (2017-2030)
  • Table 73 Market size of Epilepsy by current therapies in Spain, in USD Million (2017-2030)
  • Table 74 Market size of Epilepsy by emerging therapies in Spain, in USD Million (2017-2030)
  • Table 75 Total Market Size of Epilepsy in the UK, in USD Million (2017-2030)
  • Table 76 Market size of Epilepsy by current therapies in the UK, in USD Million (2017-2030)
  • Table 77 Market size of Epilepsy by emerging therapies in the UK, in USD Million (2017-2030)
  • Table 78 Total Market Size of Epilepsy in Japan, in USD Million (2017-2030)
  • Table 79 Market size of Epilepsy by current therapies in Japan, in USD Million (2017-2030)

List of Figures

  • Figure 1 ILAE 2017 Classification of Seizure Types Basic Version
  • Figure 2 ILAE 2017 Classification of Seizure Types Extended Version
  • Figure 3 Classification of Seizure
  • Figure 4 Pathophysiology of Epilepsy
  • Figure 5 Total Prevalent Population of Epilepsy in the 7MM (2017-2030)
  • Figure 6 Total Diagnosed Prevalent Population of Epilepsy in the 7MM (2017-2030)
  • Figure 7 Total Prevalent Population of Epilepsy in the US (2017-2030)
  • Figure 8 Total Diagnosed Prevalent Population of Epilepsy in the US (2017-2030)
  • Figure 9 Gender-specific Diagnosed Prevalence of Epilepsy in the US (2017-2030)
  • Figure 10 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in the US (2017-2030)
  • Figure 11 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in the US (2017-2030)
  • Figure 12 Total Prevalent Population of Epilepsy in Germany (2017-2030)
  • Figure 13 Total Diagnosed Prevalent Population of Epilepsy in Germany (2017-2030)
  • Figure 14 Gender-specific Diagnosed Prevalence of Epilepsy in Germany (2017-2030)
  • Figure 15 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Germany (2017-2030)
  • Figure 16 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Germany (2017-2030)
  • Figure 17 Total Prevalent Population of Epilepsy in France (2017-2030)
  • Figure 18 Total Prevalent Diagnosed Population of Epilepsy in France (2017-2030)
  • Figure 19 Gender-specific Diagnosed Prevalence of Epilepsy in France (2017-2030)
  • Figure 20 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in France (2017-2030)
  • Figure 21 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in France (2017-2030)
  • Figure 22 Total Prevalent Population of Epilepsy in Italy (2017-2030)
  • Figure 23 Total Diagnosed Prevalent Population of Epilepsy in Italy (2017-2030)
  • Figure 24 Gender-specific Diagnosed Prevalence of Epilepsy in Italy (2017-2030)
  • Figure 25 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Italy (2017-2030)
  • Figure 26 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Italy (2017-2030)
  • Figure 27 Total Prevalent Population of Epilepsy in Spain (2017-2030)
  • Figure 28 Total Diagnosed Prevalent Population of Epilepsy in Spain (2017-2030)
  • Figure 29 Gender-specific Diagnosed Prevalence of Epilepsy in Spain (2017-2030)
  • Figure 30 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Spain (2017-2030)
  • Figure 31 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Spain (2017-2030)
  • Figure 32 Total Prevalent Population of Epilepsy in the UK (2017-2030)
  • Figure 33 Total Diagnosed Prevalent Population of Epilepsy in the UK (2017-2030)
  • Figure 34 Gender-specific Diagnosed Prevalence of Epilepsy in the UK (2017-2030)
  • Figure 35 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in the UK (2017-2030)
  • Figure 36 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in the UK (2017-2030)
  • Figure 37 Total Prevalent Population of Epilepsy in Japan (2017-2030)
  • Figure 38 Total Diagnosed Prevalent Population of Epilepsy in Japan (2017-2030)
  • Figure 39 Gender-specific Diagnosed Prevalence of Epilepsy in Japan (2017-2030)
  • Figure 40 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Japan (2017-2030)
  • Figure 41 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Japan (2017-2030)
  • Figure 42 Unmet Needs of Epilepsy
  • Figure 43 Seven Major Market Size of Epilepsy in USD Million (2017-2030)
  • Figure 44 Total Market Size of Epilepsy in the US, USD Millions (2017-2030)
  • Figure 45 Market size of Epilepsy by current therapies in the US, in USD Million (2017-2030)
  • Figure 46 Market size of Epilepsy by emerging therapies in the US, in USD Million (2017-2030)
  • Figure 47 Total Market Size of Epilepsy in Germany, USD Millions (2017-2030)
  • Figure 48 Market size of Epilepsy by current therapies in Germany, in USD Million (2017-2030)
  • Figure 49 Market size of Epilepsy by emerging therapies in Germany, in USD Million (2017-2030)
  • Figure 50 Total Market Size of Epilepsy in France, USD Millions (2017-2030)
  • Figure 51 Market size of Epilepsy by current therapies in France, in USD Million (2017-2030)
  • Figure 52 Market size of Epilepsy by emerging therapies in France, in USD Million (2017-2030)
  • Figure 53 Total Market Size of Epilepsy in Italy, USD Millions (2017-2030)
  • Figure 54 Market size of Epilepsy by current therapies in Italy, in USD Million (2017-2030)
  • Figure 55 Market size of Epilepsy by emerging therapies in Italy, in USD Million (2017-2030)
  • Figure 56 Total Market Size of Epilepsy in Spain, USD Millions (2017-2030)
  • Figure 57 Market size of Epilepsy by current therapies in Spain, in USD Million (2017-2030)
  • Figure 58 Market size of Epilepsy by emerging therapies in Spain, in USD Million (2017-2030)
  • Figure 59 Total Market Size of Epilepsy in the UK, USD Millions (2017-2030)
  • Figure 60 Market size of Epilepsy by current therapies in the UK, in USD Million (2017-2030)
  • Figure 61 Market size of Epilepsy by emerging therapies in the UK, in USD Million (2017-2030)
  • Figure 62 Total Market Size of Epilepsy in Japan, USD Millions (2017-2030)
  • Figure 63 Market size of Epilepsy by current therapies in Japan, in USD Million (2017-2030)
  • Figure 64 Market size of Epilepsy by emerging therapies in Japan, in USD Million (2017-2030)
  • Figure 65 Market Drivers
  • Figure 66 Market Barriers
  • Figure 67 SWOT Analysis of Epilepsy

DelveInsight's 'Epilepsy - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Epilepsy market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Epilepsy market size from 2017 to 2030. The report also covers current Epilepsy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Epilepsy Disease Understanding and Treatment Algorithm

Epilepsy Overview

According to the American Association of Neurological Surgeons, epilepsy is a disorder of the brain characterized by repeated seizures. A seizure is usually defined as a sudden alteration of behavior due to a temporary change in the electrical functioning of the brain. Normally, the brain continuously generates tiny electrical impulses in an orderly pattern. These impulses travel along neurons - the network of nerve cells in the brain - and throughout the whole body via chemical messengers called neurotransmitters. In epilepsy, the brain's electrical rhythms tend to become imbalanced, resulting in recurrent seizures. Moreover, in patients with seizures, the normal electrical pattern is disrupted by sudden and synchronized bursts of electrical energy that may briefly affect their consciousness, movements, or sensations.

Epilepsies have many possible causes, and there are several types of seizures. Anything that disturbs the normal pattern of neuron activity - from illness to brain damage to abnormal brain development - can lead to seizures.

Epilepsy may develop because of an abnormality in brain wiring, an imbalance of nerve signaling chemicals called neurotransmitters, changes in important features of brain cells called channels, or some combination of these and other factors.

If seizures ascend from a specific area of the brain, then the initial symptoms of the seizure often reflect the functions of that area. The right half of the brain controls the left side of the body, and the left half of the brain controls the right side of the body. For example, if a seizure starts from the right side of the brain in the area that controls movement in the thumb, then the seizure may begin with jerking of the left thumb or hand.

Epilepsy Diagnosis

Several tests are used to determine whether a person has a form of epilepsy and, if so, what kind of seizures the person has. These tests include:

  • Imaging and Monitoring - This diagnostic test helps to records electrical activity detected by electrodes placed on the scalp. An electroencephalogram, or EEG, can assess whether there are any detectable abnormalities in the person's brain waves and may help to determine if anti-seizure drugs would be beneficial. The most commonly used brain scans include CT (computed tomography), PET (positron emission tomography), and MRI (magnetic resonance imaging). CT and MRI scans reveal structural abnormalities of the brain, such as tumors and cysts, which may cause seizures. PET scans can be used to identify brain regions with lower than normal metabolism, a feature of the epileptic focus after the seizure has stopped.
  • Medical History - It is an essential part of the diagnosis of epilepsy. Taking a detailed medical history, including symptoms and duration of the seizures, is still one of the best methods available to determine what kind of seizures a person has had and to determine any form of epilepsy. The medical history should include details about any past illnesses or other symptoms a person may have had, as well as any family history of seizures. Since people who have suffered a seizure do not often remember what happened, caregivers or other accounts of seizures are vital to this evaluation. The person who experienced the seizure is asked about any warning experiences. The observers will be asked to provide a detailed description of events in the timeline they occurred.
  • Blood Tests - In the emergency department, it is standard procedure to screen for exposure to recreational drugs in anyone with a first seizure. Blood samples may be taken to screen for metabolic or genetic disorders that may be associated with the seizures. They also may be used to check for underlying health conditions such as infections, lead poisoning, anemia, and diabetes that may be causing or triggering the seizures.
  • Developmental, Neurological, and Behavioral Tests - Tests devised to measure motor abilities, behavior, and intellectual ability are often used to determine how epilepsy is affecting an individual. These tests also can provide clues about what kind of epilepsy the person has.

Epilepsy Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Epilepsy, Total Diagnosed Prevalent Population of Epilepsy Gender-specific Diagnosed Prevalence of Epilepsy and Diagnosed Prevalence of Epilepsy Based on Seizure types in adults, Diagnosed Prevalence of Epilepsy Based on Seizure types in children in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings

This section provides glimpse of the Epilepsy epidemiology in the 7MM.

  • The total prevalent population of Epilepsy in the seven major markets was found to be 7,190,297 in 2017. However, the total diagnosed prevalent population in the 7MM was 5,216,490 in 2017.
  • The diagnosed prevalent cases of Epilepsy, in the United States, were found to be 2,808,599 in 2017.
  • In the United States, the number of cases of Generalized, Focal and Other determined and undetermined Epileptic seizures in Adults was 770,288, 1,482,440 and 169,560, respectively, in 2017.
  • In the United States, the number of cases of Generalized, Focal and Other determined and undetermined Epileptic seizures in Children was 158,387, 212,471 and 15,452, respectively, in 2017.
  • It was also found that in the United States, the number of males and females with Epilepsy was 1,477,323 and 1,331,276, respectively, in 2017.
  • In the EU5 countries, the prevalence of Epilepsy was found to be maximum in Germany with 645,784 cases, followed by the United Kingdom with 641,720 cases in 2017. While, the least number of cases were found in Spain, with 403,591 cases in 2017.
  • In Japan, the total prevalence of Epilepsy was estimated to be 1,012,659 in 2017.

Country wise- Epilepsy Epidemiology

The epidemiology segment also provides the Epilepsy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Epilepsy Drug Chapters

The drug chapter segment of the Epilepsy report encloses the detailed analysis of Epilepsy marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Epilepsy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Epilepsy Marketed Drugs

Valtoco: Neurelis

Valtaco is a proprietary formulation of diazepam incorporating the unique combination of a vitamin E-based solution and Intravail absorption enhancement with the goal of obtaining unparalleled absorption, tolerability, and reliability in a nasal formulation. It is delivered via a nasal formulation in a spray, being developed for the management of pediatric and adult patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity, also known as cluster seizures. The exact mechanism of action for diazepam is not fully understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor. In January 2020, the US FDA approved Valtoco (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in people with epilepsy 6 years of age and older.

Product details in the report…

Epidiolex: Greenwich Biosciences

Epidiolex (also known as Epidyolex in Europe) is the first prescription, plant-derived cannabis oral formulation developed by the GW pharmaceuticals. It is a novel class of antiepileptic medications with a different mechanism of action. It has been approved in the US and Europe for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older. The drug is the first FDA-approved drug that contains a purified drug substance derived from marijuana, and the active ingredient is cannabidiol (CBD). Under the controlled substances act (CSA), CBD is classified as a Schedule I substance; thus, GW Pharmaceuticals conducted nonclinical and clinical studies to assess the abuse potential of CBD to support its usage. Based on these results, DAE has rescheduled the drug to enable the launch in the US.

Product details in the report…

Fintepla (ZX 008): Zogenix

Fintepla (ZX008), developed by Zogenix, is an oral medication that is a low-dose solution of fenfluramine hydrochloride. It prevents the entry of calcium ions into nerve cells, lowering their over-excitability and reducing seizure episodes. ZX008 also activates serotonin receptors, which contributes to the overall antiepileptic action. In March 2019, the company entered into an exclusive distribution agreement with Nippon Shinyaku to support the sales and distribution of the product in Japan, if approved. Fintepla is also under late-stage development to treat seizures associated with Lennox-Gastaut syndrome (LGS), another rare and devastating form of childhood-onset epilepsy. Additionally, the company evaluates Fintepla in other rare epileptic syndromes and diseases in Phase II and investigator-initiated Studies.

Product details in the report…

Briviact: UCB Biopharma

UCB Biopharma has developed Briviact to treat partial-onset seizures in patients 4 years of age and older. It is initially indicated for the treatment of partial-onset seizures (also called focal seizures) only in adult patients (16 years of age and older). This means that Briviact has been approved for use in patients who are also on other seizure medications. Studies of Briviact have shown that it significantly lowers down the frequency of partial seizures as compared to people taking a placebo or inactive drug. The active ingredient in Briviact is brivaracetam-the newest antiepileptic drug (AED) in the 'racetam' class of medicines and has a high and selective affinity toward the synaptic vesicle protein 2A (SV2A) in the brain and is responsible for the anticonvulsant activity. Brivaracetam acts by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A), like levetiracetam, but with 20-fold greater affinity. There is some evidence that racetams, including levetiracetam and brivaracetam access the luminal side of recycling synaptic vesicles during vesicular endocytosis.

Product details in the report…

Xcopri (cenobamate): SK Life Science

Cenobamate is an FDA-approved anti-epileptic drug (AED) for the treatment of partial-onset seizures in adults. In the US, the drug is marketed under the brand name Xcopri (cenobamate tablets) CV. It was discovered and developed by SK Biopharmaceuticals and SK life science. In 2019, SK Biopharmaceuticals entered into an exclusive licensing agreement with Arvelle Therapeutics to develop and commercialize cenobamate in Europe. The European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) Arvelle filed for cenobamate for the adjunctive treatment of focal-onset (partial-onset) seizures in adults.

Product details in the report…

Nayzilam (midazolam), nasal spray CIV: UCB

Nayzilam (also known midazolam; formerly ITI-111) is an investigational midazolam formulation being developed by Upsher-Smith. It is being developed for the rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity, such as seizure clusters or acute repetitive seizures; it is intended to be delivered intranasally without active inhalation by the patient. The novel, a small molecule, works as a GABA receptor agonist. The exact mechanism of action for midazolam is not fully understood; however, it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor. UCB acquired Nayzilam from Proximagen in June 2018. In 2019, Nayzilam (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for epilepsy seizure clusters, was launched in the US.

Product details in the report…

Diacomit: Biocodex

Diacomit (stiripentol), an original anti-epileptic drug resulting from Biocodex's research program, is indicated for treating seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam. There are no clinical data to support the use of Diacomit as monotherapy in Dravet syndrome. The drug's chemical structure is not related to any other known anticonvulsant, and its active substance is stiripentol. The mechanism by which Diacomit exerts its anticonvulsant effect in humans is unknown. Possible mechanisms of action include direct effects mediated through the gamma-aminobutyric acid (GABAA receptor) and indirect effects involving inhibition of cytochrome P450 activity with resulting increase in blood levels of clobazam and its active metabolite. It is available in a dosage of 250 mg and 500 mg, both in hard capsules and powder for oral suspension..

Product details in the report…

Epilepsy Emerging Drugs

Ganaxolone: Marinus Pharmaceuticals

Marinus Pharmaceuticals is developing Ganaxolone, a synthetic analog of allopregnanolone, an endogenous neurosteroid produced in the central nervous system that modulates the brain neurotransmitter GABA. It is an allosteric modulator of GABAA receptors acting through binding sites that are distinct from the benzodiazepine binding site. Ganaxolone has been designed with an added methyl group that prevents back conversion to an active steroid, which unlocks ganaxolone's potential for chronic use. In preclinical studies, ganaxolone exhibited potency and efficacy comparable to allopregnanolone Ganaxolone is a CNS-selective GABA-A modulator being developed in three different dose forms (IV, capsule, and liquid) intended to maximize therapeutic reach to adult and pediatric patients in both acute and chronic care settings. The drug is currently being developed in three different dose forms (IV, capsule, and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is currently conducting studies in CDKL5 deficiency disorder (Phase III), PCDH19-related epilepsy (Phase II), and refractory status epilepticus (Phase III).

Product details in the report…

AQST-203: Aquestive Therapeutics

Aquestive Therapeutics is developing AQST-203 (also known as Diazepam buccal soluble film; DBF; DBSF; Diazepam BSF; Libervant). It is a novel formulation of diazepam as a small, thin-film strip for placement inside the cheek. It is a buccal soluble film formulation of diazepam in development as rescue therapy for patients with epilepsy who are already taking antiepileptic medications and who require occasional use of diazepam to control bouts of increased seizure activity. The drug leverages Aquestive's proprietary PharmFilm technology and is in development to select patients with refractory epilepsy who require intermittent use of diazepam to control episodes of increased seizure activity or seizure clusters. In September 2020, Aquestive Therapeutics announced that the US FDA has issued a complete response letter (CRL) regarding the New Drug Application (NDA) for Libervant (diazepam) Buccal Film for management of seizure clusters.

Product details in the report…

Cannabidiol: Insys Therapeutics

Insys Therapeutics is developing synthetic Cannabidiol (CBD), an orally administered small molecule that acts as Cannabinoid Receptor CB1 Antagonist. It is a major phytocannabinoid, isolated from Cannabis sativa extract. CBD is considered to have a wider scope of medical applications. Currently, it is in phase III for Infantile spasms and is also being investigated in the phase II stage of development to treat childhood absence epilepsy. It was also investigated under the phase III stage of development to treat severe pediatric epileptic syndromes, including Dravet syndrome and Lennox-Gastout syndrome.

Product details in the report…

Padsevonil: UCB

Product details in the report…

Soticlestat (TAK935/OV935): Takeda/Ovid Therapeutics

Product details in the report…

Zygel (ZYN002): Zynerba Pharma

Product details in the report…

Epilepsy Market Outlook

According to the American Association of Neurological Surgeons, epilepsy is a disorder of the brain characterized by repeated seizures. A seizure is usually defined as a sudden alteration of behavior due to a temporary change in the brain's electrical functioning. Usually, the brain continuously generates tiny electrical impulses in an orderly pattern. The epilepsies have many possible causes, and there are several types of seizures. Anything that disturbs the normal neuron activity pattern-from illness to brain damage to abnormal brain development-can lead to seizures. In patients with seizures, the normal electrical pattern is disrupted by sudden and synchronized bursts of electrical energy that may briefly affect their consciousness, movements, or sensations.

The treatment paradigm of epilepsy or its management strategies involves three main categories, i.e., pharmacotherapy, surgery, and alternative treatment strategies, including neurostimulation, ketogenic diet, and lifestyle changes. Medical professionals decide the treatment line according to the patient condition and severity of the case. Medications that have been tested in rigorous scientific trials and gotten approval from the USFDA are the mainstay of epilepsy treatment.

The first line anti-epileptic medications (AEDs) can be classified as Sodium Channel Modulators (Phenytoin, lacosamide, Briviact, Lamictal, Aptiom, Depakene), Gamma-Aminobutyric Acid (GABA) Receptor Modulator (Xcopri, Topamax, Clobazam, and others), Calcium Channel Blockers, Receptor Blockers, Synaptic vesicle protein SV2A Modulator, Na/Ca Channel modulators, other Mono or Combo therapies (AMPA Receptor Blockade). The second line of therapies includes Mono or Combo AEDs. Also, the adjunctive treatment includes Epidiolex (Cannabidiol) and Fintepla (Fenluramine).

Apart from these anti-epileptic drugs, several other drugs are also used, such as Fycompa, Felbamate, Neurontin (gabapentin), Ezogabine, Primidone, Eslicarbazepine, Stiripentol, Tiagabine, Sabril, Lyrica (pregabalin), Trileptal (oxcarbazepine), etc. as an add on therapy for epilepsy.

The epilepsy pipeline possesses multiple potential drugs in late- and mid-stage developments that are to be launched shortly. Key players involved in robust research and development for epilepsy include Aquestive Therapeutics, UCB Bio Pharma, Cavion Pharmaceuticals, Takeda/ Ovid Therapeutics, Pfizer/ Cerevel Therapeutics, Insys Therapeutics, Engage Therapeutics, Zynerba Pharma, Zogenix, Marinus Pharmaceuticals, Jazz Pharmaceuticals, and others.

Diet therapy can also be utilized in some patients with specific forms of epilepsy. The most common diets utilized are the ketogenic diet and the modified Atkins diet. The ketogenic diet is a special high-fat, adequate-protein, and low carbohydrate diet that is initiated over 3-4 days in the hospital. The modified Atkins diet is similar to the ketogenic diet but is slightly less restrictive.

The other treatment option available is surgery. Surgery offers the finest chance of broad control of seizures in patients whose seizures are medically resistant. Pre-surgical evaluation consists of a one- or two-phase process to determine if surgery is the best option and can provide good seizure control with minimal risk. Phase I involves all non-invasive (non-surgical) tests. Phase II testing involves invasive tests (requires surgery) that are used in select patients.

Key Findings

This section includes a glimpse of the Epilepsy 7MM market.

  • The market size of Epilepsy in the seven major markets was estimated to be USD 1,847.46 Million in 2017.
  • The United States accounts for the largest market size of Epilepsy, in comparison to EU5 (the United Kingdom, Germany, Italy, Spain, and France) and Japan.
  • Among the EU5 countries, the United Kingdom had the highest market size with USD 118.23 Million in 2017, while France had the lowest market size of Epilepsy with USD 72.65 Million in 2017.
  • The Japan Epilepsy market accounted for USD 121.90 Million in 2017.

The United States Market Outlook

This section provides the total Epilepsy market size and market size by therapies in the United States.

EU-5 Market Outlook

The total Epilepsy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Epilepsy market size and market size by therapies in Japan are provided.

Epilepsy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Epilepsy market or expected to get launched in the market during the study period 2017-2030. The analysis covers Epilepsy market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Epilepsy Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Epilepsy emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Epilepsy market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Epilepsy, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Epilepsy epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Epilepsy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Epilepsy market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Epilepsy market.

Report Highlights:

  • In the coming years, Epilepsy market is set to change due to the rising awareness of the disease, increased diagnosis and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Epilepsy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • As per DelveInsight's analysis, Epilepsy can be of three kinds on the basis of seizure-type, namely, Generalized, Focal and other determined and undetermined seizures. These seizures come with a slight variation in children as well as adults.
  • Delveinsight has also analysed gender-specific data regarding Epilepsy, which suggests that it is more prevalent in males than in females.
  • Expected Launch of potential therapies, Libervant/ Diazepam Buccal Soluble Film (Aquestive Therapeutics), UCB0942/Padsevonil (UCB Biopharma), Soticlestat (TAK-935/OV935) (Takeda), CX-8998 (Jazz Pharmaceuticals), Ganaxolone (Marinus Pharmaceuticals), PF-06372865/ CVL-865 (Pfizer/ Cerevel Therapeutics), Cannabidiol Oral Solution (Insys Therapeutics), Staccato Alprazolam (EngageTherapeutics/ UCB), GWP42003-P (GW Research), Fintepla (Zogenix), Perampenal (Eisai) and Zygel (Zynerba), may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of Epilepsy.
  • Currently, the first line treatment of Epilepsy involves the use AEDs either as monotherapies or combination therapy. Additionally, the second line and third line treatment option for epileptic patients also involves the use of AEDs itself. However, the third line treatment option also includes Surgery, VNS, Deep Brain stimulation, etc. Furthermore, certain Mono or Adjunctive therapies are also used for treating Epilepsy.

Epilepsy Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Epilepsy Pipeline Analysis
  • Epilepsy Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Epilepsy Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • Epilepsy Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Epilepsy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Epilepsy market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Epilepsy total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Epilepsy market size during the forecast period (2020-2030)?
  • At what CAGR, the Epilepsy market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the Epilepsy market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the Epilepsy market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Epilepsy?
  • What is the historical Epilepsy patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Epilepsy at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Epilepsy?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Epilepsy during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Epilepsy along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Epilepsy in the US and Europe?
  • What are the Epilepsy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Epilepsy?
  • How many therapies are developed by each company for the treatment of Epilepsy?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Epilepsy?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Epilepsy therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Epilepsy and their status?
  • What are the key designations that have been granted for the emerging therapies for Epilepsy?
  • What are the 7MM historical and forecasted market of Epilepsy?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Epilepsy.
  • To understand the future market competition in the Epilepsy market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Epilepsy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Epilepsy market.
  • To understand the future market competition in the Epilepsy market.

Table of Contents

1 Key Insights

2 Epilepsy Market Overview at a Glance

  • 2.1 Market Share (%) Distribution of Epilepsy in 2017
  • 2.2 Market Share (%) Distribution of Epilepsy in 2030

3 Executive Summary

4 Disease Background and Overview

  • 4.1 Introduction
  • 4.2 Seizure Types
    • 4.2.1 Generalized Seizures
    • 4.2.2 Focal Seizure
    • 4.2.3 Unknown Seizures
  • 4.3 Clinical Manifestations
  • 4.4 Causes
  • 4.5 Classification
    • 4.5.1 Generalized onset seizures
    • 4.5.2 Focal onset seizures
    • 4.5.3 Unknown onset seizures
  • 4.6 Types of Epilepsies
    • 4.6.1 West Syndrome
    • 4.6.2 Dravet syndrome
    • 4.6.3 Lennox-Gastaut syndrome
    • 4.6.4 Landau-Kleffner syndrome
    • 4.6.5 Epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS)
    • 4.6.6 CDKL5 deficiency disorder (CDD)
  • 4.7 Risk Factors
  • 4.8 Pathophysiology
  • 4.9 Diagnosis
    • 4.9.1 Imaging and Monitoring
    • 4.9.2 Medical History
    • 4.9.3 Blood Tests
    • 4.9.4 Developmental, Neurological, and Behavioral Tests
  • 4.1 Tuberous Sclerosis Complex (TSC) Mutations in Epilepsy

5 Epidemiology and Patient Population

  • 5.1 Key Findings
  • 5.2 7MM Total Prevalent Population of Epilepsy
  • 5.3 7MM Diagnosed Total Prevalent Population of Epilepsy

6 Country-wise Epidemiology of Epilepsy

  • 6.1 United States
    • 6.1.1 Assumptions and Rationale
    • 6.1.2 Total Prevalent Population of Epilepsy in the United States
    • 6.1.3 Total Diagnosed Prevalent Population of Epilepsy in the United States
    • 6.1.4 Gender-specific Diagnosed Prevalence of Epilepsy in the United States
    • 6.1.5 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in the United States
    • 6.1.6 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in the United States
  • 6.2 EU5 Countries
    • 6.2.1 Assumptions and Rationale
  • 6.3 Germany
    • 6.3.1 Assumptions and Rationale
    • 6.3.2 Total Prevalent Population of Epilepsy in Germany
    • 6.3.3 Total Diagnosed Prevalent Population of Epilepsy in Germany
    • 6.3.4 Gender-specific Diagnosed Prevalence of Epilepsy in Germany
    • 6.3.5 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Germany
    • 6.3.6 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Germany
  • 6.4 France
    • 6.4.1 Assumptions and Rationale
    • 6.4.2 Total Prevalent Population of Epilepsy in France
    • 6.4.3 Total Diagnosed Prevalent Population of Epilepsy in France
    • 6.4.4 Gender-specific Diagnosed Prevalence of Epilepsy in France
    • 6.4.5 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in France
    • 6.4.6 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in France
  • 6.5 Italy
    • 6.5.1 Assumptions and Rationale
    • 6.5.2 Total Prevalent Population of Epilepsy in Italy
    • 6.5.3 Total Diagnosed Prevalent Population of Epilepsy in Italy
    • 6.5.4 Gender-specific Diagnosed Prevalence of Epilepsy in Italy
    • 6.5.5 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Italy
    • 6.5.6 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Italy
  • 6.6 Spain
    • 6.6.1 Assumptions and Rationale
    • 6.6.2 Total Prevalent Population of Epilepsy in Spain
    • 6.6.3 Total Diagnosed Prevalent Population of Epilepsy in Spain
    • 6.6.4 Gender-specific Diagnosed Prevalence of Epilepsy in Spain
    • 6.6.5 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in Spain
    • 6.6.6 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in Spain
  • 6.7 United Kingdom
    • 6.7.1 Assumptions and Rationale
    • 6.7.2 Total Prevalent Population of Epilepsy in the United Kingdom
    • 6.7.3 Total Diagnosed Prevalent Population of Epilepsy in the United Kingdom
    • 6.7.4 Gender-specific Diagnosed Prevalence of Epilepsy in the United Kingdom
    • 6.7.5 Diagnosed Prevalence of Epilepsy Based on Seizure types in Adults in the United Kingdom
    • 6.7.6 Diagnosed Prevalence of Epilepsy Based on Seizure types in Children in the United Kingdom
  • 6.8 Japan
    • 6.8.1 Assumptions and Rationale
    • 6.8.2 Total Prevalent Population of Epilepsy in Japan
    • 6.8.3 Total Diagnosed Prevalent Population of Epilepsy in Japan
    • 6.8.4 Gender-specific Diagnosed Prevalence of Epilepsy in Japan
    • 6.8.5 Diagnosed Prevalence of Epilepsy on Seizure types in Adults in Japan
    • 6.8.6 Diagnosed Prevalence of Epilepsy on Seizure types in Children in Japan

7 Treatment

  • 7.1 Antiepileptic Medications (AEDs)
    • 7.1.1 Sodium Channel Modulator
    • 7.1.2 Gamma-aminobutyric Acid (GABA) Receptor Modulator
    • 7.1.3 Calcium Channel Blockers
    • 7.1.4 Receptor Blockers
    • 7.1.5 Others
  • 7.2 Diet Therapy
  • 7.3 Surgery
    • 7.3.1 Phase I Evaluation (Noninvasive Tests)
    • 7.3.2 Phase II Evaluation (Invasive Monitoring)
  • 7.4 Living and Coping with Epilepsy

8 United States Guideline on Epilepsy

9 European Guideline on Epilepsy

  • 9.1 Pharmacological Treatment
    • 9.1.1 AED options by seizure type
    • 9.1.2 AED options by epilepsy syndrome
  • 9.2 Treatment options in the management of epilepsy in patients with TSC
  • 9.3 Epilepsy treatment in TSC: Clinical Recommendations

10 Recognized Establishments

11 Unmet Needs

12 Marketed Drugs

  • 12.1 Key Competitors
  • 12.2 Valtoco: Neurelis
    • 12.2.1 Product Description
    • 12.2.2 Regulatory Milestones
    • 12.2.3 Other Developmental Activities
    • 12.2.4 Safety and Efficacy
    • 12.2.5 Product Profile
  • 12.3 Diacomit: Biocodex
    • 12.3.1 Drug Description
    • 12.3.2 Regulatory Milestones
    • 12.3.3 Other Developmental Activities
    • 12.3.4 Safety and Efficacy
    • 12.3.5 Product Profile
  • 12.4 Sympazan (clobazam): Aquestive Therapeutics
    • 12.4.1 Product Description
    • 12.4.2 Regulatory Milestones
    • 12.4.3 Other Developmental Activities
    • 12.4.4 Safety and Efficacy
    • 12.4.5 Product Profile
  • 12.5 Lamictal: GlaxoSmithKline
    • 12.5.1 Drug Description
    • 12.5.2 Regulatory Milestones
    • 12.5.3 Safety and Efficacy
    • 12.5.4 Product Profile
  • 12.6 Felbatol: Meda Pharmaceuticals
    • 12.6.1 Drug Description
    • 12.6.2 Other Developmental Activities
    • 12.6.3 Safety and Efficacy
    • 12.6.4 Product Profile
  • 12.7 Klonopin: Roche
    • 12.7.1 Drug Description
    • 12.7.2 Regulatory Milestones
    • 12.7.3 Product Profile
  • 12.8 Onfi: Lundbeck
    • 12.8.1 Drug Description
    • 12.8.2 Regulatory Milestones
    • 12.8.3 Other Developmental Activities
    • 12.8.4 Safety and Efficacy
    • 12.8.5 Product Profile
  • 12.9 Epidiolex: Greenwich Biosciences
    • 12.9.1 Drug Description
    • 12.9.2 Regulatory Milestones
    • 12.9.3 Other Developmental Activities
    • 12.9.4 Safety and Efficacy
    • 12.9.5 Current Pipeline Activity
    • 12.9.6 Product Profile
  • 12.1 Banzel: Eisai Pharmaceuticals
    • 12.10.1 Drug Description
    • 12.10.2 Regulatory Milestones
    • 12.10.3 Other Developmental Activities
    • 12.10.4 Safety and Efficacy
    • 12.10.5 Product Profile
  • 12.11 Topamax: Janssen Pharmaceuticals
    • 12.11.1 Drug Description
    • 12.11.2 Regulatory Milestones
    • 12.11.3 Safety and Efficacy
    • 12.11.4 Product Profile
  • 12.12 Zonegran: Eisai
    • 12.12.1 Drug Description
    • 12.12.2 Regulatory Milestones
    • 12.12.3 Commercial Activities
    • 12.12.4 Product Profile
  • 12.13 Fintepla (ZX 008): Zogenix
    • 12.13.1 Product Description
    • 12.13.2 Regulatory Milestone
    • 12.13.3 Other Developmental Activities
    • 12.13.4 Safety and Efficacy
    • 12.13.5 Clinical Pipeline Activity
    • 12.13.6 Product Profile
  • 12.14 Nayzilam (midazolam), nasal spray CIV: UCB
    • 12.14.1 Product Description
    • 12.14.2 Regulatory Milestone
    • 12.14.3 Other Developmental Activities
    • 12.14.4 Safety and Efficacy
    • 12.14.5 Product Profile
  • 12.15 Xcopri (cenobamate): SK Life Science
    • 12.15.1 Product Description
    • 12.15.2 Regulatory Milestone
    • 12.15.3 Other Developmental Activities
    • 12.15.4 Safety and Efficacy
    • 12.15.5 Clinical Pipeline Activity
    • 12.15.6 Product Profile
  • 12.16 H.P. Acthar Gel: Questcor Pharmaceuticals/Mallinckrodt Pharmaceuticals
    • 12.16.1 Drug Description
    • 12.16.2 Regulatory Milestones
    • 12.16.3 Other Development Activities
    • 12.16.4 Safety and Efficacy
    • 12.16.5 Product Profile
  • 12.17 Trokendi XR: Supernus Pharmaceuticals
    • 12.17.1 Drug Description
    • 12.17.2 Regulatory Milestones
    • 12.17.3 Other Developmental Activities
    • 12.17.4 Safety and Efficacy
    • 12.17.5 Product Profile
  • 12.18 Oxtellar XR: Supernus Pharmaceuticals
    • 12.18.1 Drug Description
    • 12.18.2 Regulatory Milestones
    • 12.18.3 Other Developmental Activities
    • 12.18.4 Safety and Efficacy
    • 12.18.5 Product Profile
  • 12.19 Zebinix/ Aptiom: Dainippon Sumitomo Pharma/Eisai
    • 12.19.1 Drug Description
    • 12.19.2 Regulatory Milestones
    • 12.19.3 Other Developmental Activities
    • 12.19.4 Safety and Efficacy
    • 12.19.5 Current Pipeline Activity
    • 12.19.6 Product Profile
  • 12.2 Sabril: Lundbeck
    • 12.20.1 Drug Production
    • 12.20.2 Regulatory Milestones
    • 12.20.3 Other Developmental Activities
    • 12.20.4 Safety and Efficacy
    • 12.20.5 Product Profile
  • 12.21 Fycompa: Eisai
    • 12.21.1 Drug Description
    • 12.21.2 Regulatory Milestones
    • 12.21.3 Other Developmental Activities
    • 12.21.4 Safety and Efficacy
    • 12.21.5 Current Pipeline Activity
    • 12.21.6 Product Profile
  • 12.22 Vimpat: UCB Biopharma
    • 12.22.1 Drug Description
    • 12.22.2 Regulatory Milestones
    • 12.22.3 Other Developmental Activities
    • 12.22.4 Safety and Efficacy
    • 12.22.5 Current Pipeline Activity
    • 12.22.6 Product Profile
  • 12.23 Lyrica: Pfizer
    • 12.23.1 Drug Description
    • 12.23.2 Regulatory Milestones
    • 12.23.3 Other Development Activities
    • 12.23.4 Safety and Efficacy
    • 12.23.5 Product Profile
  • 12.24 Briviact: UCB Biopharma
    • 12.24.1 Drug Description
    • 12.24.2 Regulatory Milestones
    • 12.24.3 Safety and Efficacy
    • 12.24.4 Current Pipeline Activity
    • 12.24.5 Product Profile
  • 12.25 Keppra: UCB Biopharma
    • 12.25.1 Drug Description
    • 12.25.2 Regulatory Milestones
    • 12.25.3 Other Developmental Activities
    • 12.25.4 Safety and Efficacy
    • 12.25.5 Product Profile
  • 12.26 Neurontin: Pfizer
    • 12.26.1 Drug Description
    • 12.26.2 Regulatory Milestones
    • 12.26.3 Safety and Efficacy
    • 12.26.4 Product Profile
  • 12.27 Trileptal: Novartis
    • 12.27.1 Drug Description
    • 12.27.2 Regulatory Milestones
    • 12.27.3 Other Developmental Activities
    • 12.27.4 Safety and Efficacy
    • 12.27.5 Product Profile

13 Emerging Drugs

  • 13.1 Key Competitors
  • 13.2 Ganaxolone: Marinus Pharmaceuticals
    • 13.2.1 Product Description
    • 13.2.2 Other Developmental Activities
    • 13.2.3 Clinical Development
    • 13.2.4 Safety and Efficacy
    • 13.2.5 Product Profile
  • 13.3 AQST-203: Aquestive Therapeutics
    • 13.3.1 Product Description
    • 13.3.2 Other Developmental Activities
    • 13.3.3 Clinical Development
    • 13.3.4 Safety and Efficacy
    • 13.3.5 Product Profile
  • 13.4 Cannabidiol: Insys Therapeutics
    • 13.4.1 Product Description
    • 13.4.2 Other Developmental Activities
    • 13.4.3 Clinical Development
    • 13.4.4 Safety and Efficacy
    • 13.4.5 Product Profile
  • 13.5 Padsevonil: UCB
    • 13.5.1 Product Description
    • 13.5.2 Clinical Development
    • 13.5.3 Safety and Efficacy
    • 13.5.4 Product Profile
  • 13.6 Soticlestat (TAK935/OV935): Takeda/Ovid Therapeutics
    • 13.6.1 Product Description
    • 13.6.2 Other Developmental Activities
    • 13.6.3 Clinical Development
    • 13.6.4 Product Profile
  • 13.7 Zygel (ZYN002): Zynerba Pharma
    • 13.7.1 Product Description
    • 13.7.2 Other Developmental Activities
    • 13.7.3 Clinical Development
    • 13.7.4 Product Profile
  • 13.8 ACT-709478/NBI-827104: Idorsia Pharmaceuticals/Neurocrine Biosciences
    • 13.8.1 Drug Description
    • 13.8.2 Other Development Activities
    • 13.8.3 Clinical Development
    • 13.8.4 Safety and Efficacy
    • 13.8.5 Product Profile
  • 13.9 Translarna (ataluren): PTC Therapeutics
    • 13.9.1 Product Description
    • 13.9.2 Clinical Development
    • 13.9.3 Product Profile
  • 13.1 Vatiquinone (EPI-743): PTC Therapeutics
    • 13.10.1 Drug Description
    • 13.10.2 Other Development Activities
    • 13.10.3 Clinical Development
    • 13.10.4 Product Profile
  • 13.11 JBPOS0101: BioPharm Solutions
    • 13.11.1 Product Description
    • 13.11.2 Other Development Activities
    • 13.11.3 Clinical Development
    • 13.11.4 Product Profile
  • 13.12 Natalizumab: Biogen
    • 13.12.1 Product Description
    • 13.12.2 Clinical Development
    • 13.12.3 Product Profile
  • 13.13 Staccato Alprazolam: Engage Therapeutics
    • 13.13.1 Product Description
    • 13.13.2 Other Developmental Activities
    • 13.13.3 Clinical Development
    • 13.13.4 Product Profile
  • 13.14 ICV Delivery System of Valproic Acid (CT-010): Cerebral Therapeutics
    • 13.14.1 Drug Description
    • 13.14.2 Clinical Development
    • 13.14.3 Safety and Efficacy
    • 13.14.4 Product Profile
  • 13.15 EPX-100 (Clemizole HCl): Epygenix
    • 13.15.1 Drug Description
    • 13.15.2 Other Development Activities
    • 13.15.3 Clinical Development
    • 13.15.4 Product Profile
  • 13.16 JZP-385: Jazz Pharmaceuticals
    • 13.16.1 Product Description
    • 13.16.2 Other Developmental Activities
    • 13.16.3 Clinical Development
    • 13.16.4 Safety and Efficacy
    • 13.16.5 Product Profile
  • 13.17 XEN1101: Xenon Pharmaceuticals
    • 13.17.1 Drug Description
    • 13.17.2 Other Development Activities
    • 13.17.3 Clinical Development
    • 13.17.4 Safety and Efficacy
    • 13.17.5 Product Profile
  • 13.18 PF-06372865/ CVL-865: Pfizer/ Cerevel Therapeutics
    • 13.18.1 Drug Description
    • 13.18.2 Other Development Activities
    • 13.18.3 Clinical Development
    • 13.18.4 Safety and Efficacy
    • 13.18.5 Product Profile
  • 13.19 STK-001: Stoke Therapeutics
    • 13.19.1 Drug Description
    • 13.19.2 Other Development Activities
    • 13.19.3 Clinical Development
    • 13.19.4 Safety and Efficacy
    • 13.19.5 Product Profile

14 Epilepsy: Seven Major Market Analysis

  • 14.1 Key Findings
  • 14.2 Market Size of Epilepsy in the 7MM

15 7MM Market Outlook

  • 15.1 United States Market Size
    • 15.1.1 Total Market size of Epilepsy
    • 15.1.2 Market Size by Current Therapies
    • 15.1.3 Market Size by Emerging Therapies
  • 15.2 EU5 Market Size
  • 15.3 Germany
    • 15.3.1 Total Market size of Epilepsy
    • 15.3.2 Market Size by Current Therapies
    • 15.3.3 Market Size by Emerging Therapies
  • 15.4 France
    • 15.4.1 Total Market size of Epilepsy
    • 15.4.2 Market Size by Current Therapies
    • 15.4.3 Market Size by Emerging Therapies
  • 15.5 Italy
    • 15.5.1 Total Market size of Epilepsy
    • 15.5.2 Market Size by Current Therapies
    • 15.5.3 Market Size by Emerging Therapies
  • 15.6 Spain
    • 15.6.1 Total Market size of Epilepsy
    • 15.6.2 Market Size by Current Therapies
    • 15.6.3 Market Size by Emerging Therapies
  • 15.7 United Kingdom
    • 15.7.1 Total Market size of Epilepsy
    • 15.7.2 Market Size by Current Therapies
    • 15.7.3 Market Size by Emerging Therapies
  • 15.8 Japan Market Size
    • 15.8.1 Total Market size of Epilepsy
    • 15.8.2 Market Size by Current Therapies
    • 15.8.3 Market Size by Emerging Therapies
  • 15.9 Market Access and Reimbursement

16 Case Studies

17 Market Drivers

18 Market Barriers

19 SWOT Analysis

20 Appendix

  • 20.1 Bibliography
  • 20.2 Report Methodology

21 DelveInsight Capabilities

22 Disclaimer

23 About DelveInsight

Back to Top
전화 문의
F A Q